CN111617138A - 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用 - Google Patents
痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用 Download PDFInfo
- Publication number
- CN111617138A CN111617138A CN202010647584.7A CN202010647584A CN111617138A CN 111617138 A CN111617138 A CN 111617138A CN 202010647584 A CN202010647584 A CN 202010647584A CN 111617138 A CN111617138 A CN 111617138A
- Authority
- CN
- China
- Prior art keywords
- phlegm
- heat
- medicine
- chronic obstructive
- obstructive pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 54
- 208000026435 phlegm Diseases 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 23
- 230000009798 acute exacerbation Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 241000205585 Aquilegia canadensis Species 0.000 claims description 4
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 3
- 241000877344 Strophanthus divaricatus Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 48
- 210000004072 lung Anatomy 0.000 abstract description 25
- 230000004199 lung function Effects 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 20
- 229960003957 dexamethasone Drugs 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 12
- 210000004969 inflammatory cell Anatomy 0.000 description 11
- 206010036790 Productive cough Diseases 0.000 description 9
- 210000000621 bronchi Anatomy 0.000 description 9
- 208000024794 sputum Diseases 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000000059 Dyspnea Diseases 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 241000588747 Klebsiella pneumoniae Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 210000003802 sputum Anatomy 0.000 description 7
- 206010047924 Wheezing Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000635 electron micrograph Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 210000003123 bronchiole Anatomy 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 208000037656 Respiratory Sounds Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000003456 pulmonary alveoli Anatomy 0.000 description 3
- 230000009325 pulmonary function Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 206010041232 sneezing Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003546 flue gas Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 206010043089 tachypnoea Diseases 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000594310 Randia aculeata Species 0.000 description 1
- 101100047768 Rattus norvegicus Tspan31 gene Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用。本发明通过研究痰热清对慢性阻塞性肺病急性加重模型大鼠的影响,实验结果表明痰热清高、中、低剂量均可不同程度改善慢性阻塞性肺病急性加重期大鼠肺功能、肺组织病理损伤,并呈一定的剂量依赖性;痰热清高、中、低剂量可不同程度改善炎症反应,痰热清高、中剂量优于低剂量,因此,痰热清可用于制备治疗慢性阻塞性肺病急性加重的药物。
Description
技术领域
本发明涉及痰热清的新用途领域,尤其涉及痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用。
背景技术
慢性阻塞性肺病(下文称为“COPD”)是一种慢性支气管炎、引起肺泡结构损伤的疾病的肺气肿、或者两者出现的混合并且从支气管到肺泡的气道关闭的疾病。这种疾病的症状包括:长期咳嗽带痰、由于气道阻塞引起的空气流速下降而导致的呼吸困难以及常见的呼吸道感染(诸如,普通感冒)。这种疾病在全球造成了高死亡率,并且由于吸烟、空气污染等迅速增加。
COPD的急性加重对健康状况、住院率和重返入院率以及COPD的进展造成负担影响。COPD的急性加重也是复杂的事件,常常伴随着气道炎症的加重、粘液分泌的增多以及显著的气体陷闭。这些变化导致呼吸困难这一急性加重的关键症状的加重。其他症状有痰液变浓、变多,咳嗽和喘息。
痰热清制剂由黄芩、熊胆粉、山羊角、金银花、连翘科学组方,有清热解毒、化痰、解痉、抑菌、抗病毒、解热、免疫调节等作用。临床主要可用于呼吸系统疾病、肝胆疾病、消化系统疾病等。但目前尚未有该组方在制备慢性阻塞性肺病急性加重治疗药物中应用的报道。
发明内容
本发明的目的是针对现有技术中的不足,提供痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用。
为实现上述目的,本发明采取的技术方案是:
提供了痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用。
在另一优选例中,所述痰热清的处方组成为黄芩、熊胆粉、山羊角、金银花和连翘。
在另一优选例中,所述药物还包括药剂学上可接受的辅料。
在另一优选例中,所述药物的剂型为口服给药剂型或非口服给药剂型。
在另一优选例中,所述口服给药剂型为片剂、散剂、颗粒剂、胶囊剂、乳剂、糖浆剂或喷雾剂。
在另一优选例中,所述非口服给药剂型是注射剂。
本发明通过研究痰热清对慢性阻塞性肺病急性加重模型大鼠的影响,实验结果表明痰热清高、中、低剂量均可不同程度改善慢性阻塞性肺病急性加重期大鼠肺功能、肺组织病理损伤,并呈一定的剂量依赖性;痰热清高、中、低剂量可不同程度改善炎症反应,痰热清高、中剂量优于低剂量,因此,痰热清可用于制备治疗慢性阻塞性肺病急性加重的药物。
附图说明
图1为空白对照组肺组织(左)、支气管(右)HE染色后的电镜图;
图2为模型对照组肺组织(左)、支气管(右)HE染色后的电镜图;
图3为痰热清高剂量组肺组织(左)、支气管(右)HE染色后的电镜图;
图4为痰热清中剂量组肺组织(左)、支气管(右)HE染色后的电镜图;
图5为痰热清底剂组量肺组织(左)、支气管(右)HE染色后的电镜图;
图6为地塞米松组的肺组织(左)、支气管(右)HE染色后的电镜图。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明,但不作为本发明的限定。
本实施例提供了痰热清对慢性阻塞性肺病急性加重模型大鼠的影响。
1.实验材料
1.1痰热清胶囊
生产厂家:上海凯宝药业股份有限公司,批号:1911102
处方组成:黄芩、熊胆粉、山羊角、金银花和连翘。
临床人用剂量(人以60kg计):0.06g/Kg/d
按体型系数换算成大鼠等效剂量为:
D大鼠=D人*(HI鼠/HI人)(W鼠/W人)2/3
D大鼠=D人*6.3=0.06g/kg/d*6.3=0.38g/kg/d
1.1.2地塞米松片
规格:0.75mg×100片,批号:191067,生产厂家:浙江仙琚制药股份有限公司。临用前取片剂6片共0.6g,纯化水50ml,配制成终浓度为0.012g/ml的混悬液。
用法用量:口服。成人开始剂量为1次0.75-3.00mg(1-4片),1日2-4次。维持量约1日0.75mg(1片),视病情而定。
本实验采用0.75mg/次,1日3次剂量计算。
临床人用剂量(人以60kg计):
按体型系数换算成大鼠等效剂量为:
D大鼠=D人*(HI鼠/HI人)(W鼠/W人)2/3
D大鼠=D人*6.3=0.0075mg/kg/d*6.3=0.23mg/kg/d
1.2实验动物
SD大鼠,SPF级,80只,体重260~300g,雌雄各40只。动物质量合格证号:1107261911004350,购自山东济南朋悦实验动物繁育有限公司,许可证号:SCXK(鲁)2019-0003。
饲养环境:河南中医药大学第一附属医院IVC实验室SPF级动物房,许可证号:SYXK(豫)2015-0005。环境温度(23±2)℃,湿度50%~65%,12h光照明暗交替,良好通风。动物分笼饲养于消毒塑料盒内,每笼6~8只,自由饮水。
饲料:实验动物全价营养饲料,购自斯贝福(北京)生物技术有限公司,许可证号:SCXK(京)2019-0010,饲料营养质量检测报告证明为合格。经121℃、15min湿热灭菌,干燥后备用。
饮水:纯化水,当日自制。
1.3实验试剂
红旗渠牌烤烟型过滤嘴香烟(焦油量:10mg;烟气烟碱量:1.0mg;烟气一氧化碳量:11mg;河南中烟工业公司);多聚甲醛(天津化学试剂公司);磷酸二氢钠(西安化学试剂厂);磷酸氢二钠(洛阳化学试剂厂);EDTA-K2抗凝管(上海化学试剂研究所);无水乙醇(郑州派尼化学试剂厂);IL-6、IL-10和TNF-αELISA试剂盒(规格均为:96T,武汉博士德生物工程有限公司)。CRP和SAA ELISA试剂盒(规格均为:96T,Elabscience有限公司)
细菌:肺炎克雷伯杆菌(Klebsiellapneumoniae,KP)(菌株号:46114)购自中国食品药品检定研究院中国医学细菌保藏管理中心,用前将细菌浓度调整为6×108CFU/ml。
脂多糖(LPS):购自美国Sigma公司,批号:L2880。
2.动物实验
2.1模型构建
大鼠购回后适应环境7天。灭菌饲料喂养,自由饮用灭菌水,定期检查净化及水电操作系统,保持环境安静。留取14只作为空白对照组,剩余大鼠采用香烟熏吸联合肺炎克雷伯杆菌(KP)反复感染的方法建立慢性阻塞性肺病(COPD)稳定期模型大鼠,具体方法为:点燃香烟,使烟雾浓度达到3000±500ppm,每天2次,两次吸烟间隔至少3h,共12周。第1~8周造模大鼠经鼻腔滴入KP悬液(6×108CFU/ml)0.1ml,每5天1次。经鼻腔滴入方法:以消毒的1ml注射器吸取KP悬液0.1ml,趁大鼠吸气时滴入,左、右鼻孔交替进行。第13周第一天气管内滴注脂多糖(LPS)2mg/kg建立慢性阻塞性肺疾病急性加重期大鼠模型。造模成功后将模型大鼠随机分为模型对照组、痰热清高、中、低剂量组、地塞米松组,每组12只。
2.2给药和处理
自第13周第2天开始给药,空白对照组和模型对照组给予同体积纯化水(10ml/kg/d)灌胃;其余各组分别给予痰热清高、中、低剂量和地塞米松,每日1次,给药时间为1周(如表1所示)。取材前12h所有大鼠禁食,不禁水。首先进行血常规样品的取材,取尾静脉血;之后进行大鼠腹腔注射10%乌拉坦1.0ml/100g麻醉,进行暴露式气管插管,采用动物肺功能检测系统(PFT)检测大鼠肺功能变化;腹主动脉取血,放置2h后离心取血清用于检测炎症因子IL-6、IL-10、CRP和SAA水平;开胸取出大鼠气管及全肺,将右主支气管结扎后抽取左肺肺泡灌洗液(bronchoalveolar lavage fluid,BALF),用于检测炎症因子TNF-α水平;左肺用4%的多聚甲醛灌流1h,灌流后直接固定在4%的多聚甲醛中,待进行病理检查。
表1
2.3统计学处理
数据采用SPSS 22.0软件进行统计分析。采用单因素方差分析(One-Way ANOVA)进行组间比较,符合方差齐性检验者采用最小显著值法(Least Significant Difference,LSD),不符合方差齐性检验者采用Dunnett’s T3法。结果以均数±标准差进行描述,检验水准α=0.05。
3.检测指标及结果
3.1一般状况观察
每天观察各组大鼠皮毛色泽、肢体活动、精神状况、打喷嚏及呼吸是否加深等症状。
造模两周后,模型大鼠出现不同程度的精神倦怠、进食减少;第4~8周,造模大鼠出现皮毛枯黄无光泽、倦怠喜卧,呼吸喘促,大便溏,垫料潮湿等情况;第8~12周时呼吸喘促部分伴有痰鸣,精神倦怠喜卧,口鼻部有少量分泌物,饮食进水量均减少,气管内滴注LPS后,大鼠出现较为明显的呼吸急促伴痰鸣音,部分大鼠出现咳嗽、频繁抓鼻、喷嚏等症状。给药后,痰热清高、中剂量组大鼠精神好转,呼吸喘促喉中痰鸣减轻,咳嗽、喷嚏减少,饮食进水量及活动量增多;痰热清低剂量组大鼠精神稍好转,活动量增多,呼吸急促改善不明显;地塞米松组大鼠活动增多,呼吸喘促及痰鸣减轻明显,咳嗽、喷嚏消失。
大鼠死亡情况:造模过程中5只大鼠死亡,其中1只雌鼠于造模第10周死亡,解剖示肺部肿胀,伴散在暗红色斑块及肺脓肿,1只雄鼠于急性加重期造模时麻醉过量死亡,3只大鼠(2只雄鼠,1只雌鼠)气管内滴注LPS后死亡,喉中痰鸣,呼吸困难,解剖发现肺部暗红色斑块较多,肺肿胀,其中1只肺脓肿明显,1只伴喉头水肿。给药过程中模型对照组死亡1只,解剖示支气管分泌物多,肺肿胀并呈暗红色,伴散在脓点。
3.2肺组织病理学检查
左肺用4%的多聚甲醛固定后,常规脱水,石蜡包埋,切片4μm,常规HE染色,光镜下观察肺部病理改变。每组取8张切片,每张切片在光镜下随机选取6个视野,用高清晰度彩色病理图文分析系统截取图片,计算肺泡平均截距(mean linear intercept,MLI)和平均肺泡数(mean alveolar numbers,MAN)以计算肺泡大小和密度,方法为在每张切片中间画“十”,测量其长度(L),记录肺泡隔膜数(Ns),MLI(μm)=L/Ns,另计算每个视野的肺泡数(Na),每个视野的面积(S),MAN(/mm2)=Na/S。用支气管管壁厚度(Wall thickness,Wt)表示支气管的病理变化,支气管短直径需在100-300μm范围内以规定支气管等级,在400×镜下,测量每个支气管过中心的3个长直径(c1/c2/c3)和短直径(d1/d2/d3),Wt(μm)=[(c1-d1)+(c2-d2)+(c3-d3)]/(3×2)。
对于肺组织形态观察的结果如图1-6所示:
如图1所示,空白对照组(8只):各例肺组织肺泡结构正常,肺泡腔中无明显炎症浸润,肺泡壁无明显增厚或变窄,各级细支气管结构基本正常,管腔中未见明显炎症细胞浸润;
如图2所示,模型对照组(8只):各例肺组织出现肺泡明显扩张,肺泡壁断裂,部分肺泡相互融合,肺泡腔和支气管中炎症细胞浸润,支气管壁增厚,周围可见大量炎症细胞浸润,管腔狭窄;
如图3所示,痰热清高剂量组(8只):各例肺组织可见部分肺泡扩张,肺泡腔中少量炎症细胞浸润,肺泡壁结构基本正常;各级细支气管上皮无明显脱落,支气管管腔中可见少量淋巴细胞浸润,病变程度与模型对照组比较明显减轻;
如图4所示,痰热清中剂量组(8只):各例肺组织可见部分肺泡壁断裂,肺泡腔中少量炎症细胞浸润,各级细支气管结构基本正常,上皮细胞无明显脱落,管腔中无明显炎症细胞浸润,病变程度与模型对照组比较有所减轻;
如图5所示,痰热清低剂量组(8只):各例肺组织部分肺泡壁断裂,附近肺泡融合扩张,肺泡腔及肺泡间隔可见少量炎症细胞浸润,支气管管腔及周围可见炎症细胞浸润,与模型对照组相比病变程度改善不明显;
如图6所示,地塞米松组(8只):各例肺组织可见部分肺泡壁断裂,肺泡腔增大,可见少量炎症细胞浸润,各级细支气管结构基本正常,上皮细胞无明显脱落,管腔中无明显炎症细胞浸润,与模型对照组相比病变程度有所减轻.
表2
与空白对照组比较,模型对照组MLI升高,MAN降低,支气管壁厚度增大(P<0.05);与模型对照组比较,痰热清高、中剂量组及地塞米松组MLI有降低趋势,MAN有升高趋势,无显著统计学差异(P>0.05);痰热清高剂量组和地塞米松组支气管壁厚度有所降低(P>0.05)痰热清中剂量组支气管壁厚度高于地塞米松组(P<0.05)。
3.3肺功能
取材前大鼠腹腔注射10%乌拉坦1.0ml/100g麻醉,进行暴露式气管插管,采用动物肺功能检测系统(PFT)检测每只大鼠的相关参数,包括每只大鼠的相关参数,包括用力肺活量(FVC),第0.1s用力呼气容积(FEV0.1),第0.3s用力呼气容积(FEV0.3),最大呼气流速(PEF),最大呼气中段流量(MMEF),功能残气量(FRC)等参数,各组大鼠肺功能变化如表3所示。
表3
注:n=6-12;与空白对照组比较:aP<0.05,aaP<0.01;与模型组比较:bP<0.05,bbP<0.01。
与空白对照组比较,模型对照组FVC、FEV0.3降低,FRC升高(P<0.05);与模型对照组比较,痰热清高、中、低剂量组和地塞米松组FVC均升高(P<0.05,P<0.01),痰热清高、中剂量组和地塞米松组FEV0.3、MMEF升高(P<0.05,P<0.01),痰热清高剂量组PEF升高,痰热清高、低剂量组FRC降低明显(P<0.05)。
3.4血常规
取材前尾静脉取血进行血常规检测,统计白细胞计数(WBC)、中性粒细胞比率(NEU%)、淋巴细胞百分比(%LYMPH)和单核细胞百分比(%MONO)。
表4
与空白对照组比较,模型对照组外周血WBC、NEU%显著升高,LYM%显著降低(P<0.01);与模型对照组比较,地塞米松组WBC显著降低(P<0.01),痰热清中、低剂量组降低NEU%、升高LYM%显著(P<0.05,P<0.01),痰热清高、中、低剂量及地塞米松组降低MONO%均显著(P<0.05,P<0.01);与地塞米松组比较,痰热清中、低剂量组降低NEU%、升高LYM%均显著(P<0.05,P<0.01)。
3.5血清CRP、SAA水平测定
表5
注:n=9-12。与空白对照组比较:aP<0.05,aaP<0.01;与模型组比较:bP<0.05,bbP<0.01;与低剂地塞米松组比较:ccP<0.05。
与空白对照组比较,模型对照组血清CRP、SAA水平明显升高(P<0.05,P<0.01);与模型对照组比较,地塞米松组血清SAA水平明显降低,而CRP升高(P<0.01),痰热清高剂量组有降低CRP的趋势,痰热清高、中、低剂量组有降低SAA的趋势,但无显著统计学差异(P>0.05);与地塞米松组比较,痰热清高、中、低剂量组CRP水平均显著降低(P<0.01)。
3.6血清IL-6、IL-10和肺泡灌洗液中TNF-α水平测定
采用ELISA测定血清中IL-6、IL-10和肺泡灌洗液中TNF-α表达,结果如表6所示:
表6
注:n=10-12。与空白对照组比较:aP<0.05,aaP<0.01;与模型组比较:bP<0.05,bbP<0.01;与地塞米松组比较:cP<0.05,ccP<0.01;与低剂量组比较:dP<0.05,ddP<0.01。
与空白对照组比较,模型对照组血清IL-6、BALF中TNF-α水平显著升高,血清IL-10显著降低(P<0.05,P<0.01);与模型对照组比较,痰热清高、中、低剂量组血清IL-10均显著升高(P<0.01),痰热清高、中剂量组及地塞米松组血清IL-6、BALF中TNF-α水平均降低(P<0.05,P<0.01);与地塞米松组比较,痰热清高、中、低剂量组IL-6、IL-10水平均升高(P<0.05,P<0.01),痰热清低剂量组BALF中TNF-α水平升高(P<0.05);痰热清三个剂量间比较,高剂量组IL-6较低剂量组明显降低(P<0.05),中剂量组TNF-α水平较低剂量组降低,IL-10较低剂量组升高(P<0.05)。
综上,痰热清可用于制备治疗慢性阻塞性肺病(COPD)急性加重的药物。
上所述仅为本发明较佳的实施例,并非因此限制本发明的实施方式及保护范围,对于本领域技术人员而言,应当能够意识到凡运用本发明说明书内容所作出的等同替换和显而易见的变化所得到的方案,均应当包含在本发明的保护范围内。
Claims (6)
1.痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述痰热清的处方组成为黄芩、熊胆粉、山羊角、金银花和连翘。
3.根据权利要求1所述的应用,其特征在于,所述药物还包括药剂学上可接受的辅料。
4.根据权利要求1所述的应用,其特征在于,所述药物的剂型为口服给药剂型或非口服给药剂型。
5.根据权利要求4所述的应用,其特征在于,所述口服给药剂型为片剂、散剂、颗粒剂、胶囊剂、乳剂、糖浆剂或喷雾剂。
6.根据权利要求4所述的生物转化熊胆粉在制备抗炎药物中的应用,其特征在于,所述非口服给药剂型是注射剂。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010647584.7A CN111617138A (zh) | 2020-07-07 | 2020-07-07 | 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用 |
US17/160,090 US20220008495A1 (en) | 2020-07-07 | 2021-01-27 | Application of phlegmyheatclear in preparation of drug for treatment of acute exacerbation of chronic obstructive pulmonary disease |
AU2021200606A AU2021200606B2 (en) | 2020-07-07 | 2021-01-29 | Application of phlegmyheatclear in preparation of drug for treatment of acute exacerbation of chronic obstructive pulmonary disease |
TW110103883A TWI804811B (zh) | 2020-07-07 | 2021-02-02 | 痰熱清在製備慢性阻塞性肺病急性加重治療藥物中的應用 |
KR1020210014955A KR20220005973A (ko) | 2020-07-07 | 2021-02-02 | 일종의 만성 폐쇄성 폐질환의 급성 가중 치료 약물 제조 과정에서의 담열청의 응용 |
JP2021017442A JP2022014868A (ja) | 2020-07-07 | 2021-02-05 | 慢性閉塞性肺疾患の急性増悪の治療薬の調製におけるTanreqingの応用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010647584.7A CN111617138A (zh) | 2020-07-07 | 2020-07-07 | 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111617138A true CN111617138A (zh) | 2020-09-04 |
Family
ID=72255759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010647584.7A Pending CN111617138A (zh) | 2020-07-07 | 2020-07-07 | 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220008495A1 (zh) |
JP (1) | JP2022014868A (zh) |
KR (1) | KR20220005973A (zh) |
CN (1) | CN111617138A (zh) |
AU (1) | AU2021200606B2 (zh) |
TW (1) | TWI804811B (zh) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5989340B2 (ja) * | 2009-10-11 | 2016-09-07 | レスピノヴァ リミテッド | 脈動薬物伝達プロトコル及び方法 |
CN102106914B (zh) * | 2011-01-28 | 2012-09-05 | 康美药业股份有限公司 | 治疗感染性疾病的药物、其制备方法及用途 |
KR101427290B1 (ko) * | 2012-03-22 | 2014-08-06 | 경희대학교 산학협력단 | 죽여 추출물을 유효성분으로 함유하는 만성폐쇄성 폐질환 예방 및 치료용 약학적 조성물 |
JP2016519160A (ja) * | 2013-05-22 | 2016-06-30 | パール セラピューティクス,インコーポレイテッド | 3つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム |
CN103599188B (zh) * | 2013-12-02 | 2016-05-18 | 北京三泉医药技术有限公司 | 用于清热化痰解毒的胶囊剂 |
CN103610757B (zh) * | 2013-12-02 | 2016-05-18 | 北京三泉医药技术有限公司 | 用于清热化痰解毒的注射液 |
GB201500447D0 (en) * | 2015-01-12 | 2015-02-25 | Glaxosmithkline Ip Dev Ltd | Novel Combination Product |
CN109925503B (zh) * | 2017-12-19 | 2023-05-12 | 上海凯宝药业股份有限公司 | 一种逆转金黄色葡萄球菌耐药性的中药注射剂 |
-
2020
- 2020-07-07 CN CN202010647584.7A patent/CN111617138A/zh active Pending
-
2021
- 2021-01-27 US US17/160,090 patent/US20220008495A1/en not_active Abandoned
- 2021-01-29 AU AU2021200606A patent/AU2021200606B2/en active Active
- 2021-02-02 KR KR1020210014955A patent/KR20220005973A/ko not_active Application Discontinuation
- 2021-02-02 TW TW110103883A patent/TWI804811B/zh active
- 2021-02-05 JP JP2021017442A patent/JP2022014868A/ja active Pending
Non-Patent Citations (4)
Title |
---|
俞洋等: "痰热清治疗对AECOPD患者症状、血气、肺功能指标及炎性因子水平的影响", 《现代生物医学进展》 * |
倪荟: "痰热清注射液治疗慢性阻塞性肺病急性加重期的临床疗效", 《内蒙古中医药》 * |
徐冬才等: "痰热清治疗慢性阻塞性肺病伴有急性加重的临床效果分析", 《江西医药》 * |
林观康等: "痰热清注射液对COPD大鼠体内炎症因子及气道黏液高分泌的影响", 《新中医》 * |
Also Published As
Publication number | Publication date |
---|---|
JP2022014868A (ja) | 2022-01-20 |
KR20220005973A (ko) | 2022-01-14 |
US20220008495A1 (en) | 2022-01-13 |
AU2021200606B2 (en) | 2022-03-10 |
TWI804811B (zh) | 2023-06-11 |
AU2021200606A1 (en) | 2022-01-27 |
TW202202162A (zh) | 2022-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104666828B (zh) | 贝母生物碱在制备预防或治疗慢性阻塞性肺病药物中的用途 | |
CN109999052B (zh) | β-烟酰胺单核苷酸或其前体在制备治疗或缓解呼吸障碍或疾病的药物中的用途 | |
CN112007096A (zh) | 一种中药组合物在制备治疗或预防慢性阻塞性肺炎药物中的应用 | |
CN114712453B (zh) | 一种中药组合物在抗病毒、保护脏器、提高免疫力药物中的应用 | |
CN115463142B (zh) | 柚皮苷二氢查尔酮在制备治疗肺纤维化药物中的应用 | |
CN113116907A (zh) | 环黄芪醇的医药用途 | |
CN111617138A (zh) | 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用 | |
CN111329870A (zh) | Yadanzigan在制备治疗和/或预防肺损伤的药物中的用途 | |
CN106860743B (zh) | 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法 | |
WO2016019736A1 (zh) | 用于治疗咳嗽及减轻气道炎症的五味子提取物、其制备方法及应用 | |
CN114668788A (zh) | 艾叶油包合物在制备治疗哮喘医用喷雾剂中的应用 | |
CN102198120B (zh) | 紫草萘醌类化合物的医药用途 | |
CN111084862B (zh) | 用于防治家禽肺热咳喘症的中药口服液及其制备方法 | |
CN114533752A (zh) | 柚皮苷在制备治疗慢性阻塞性肺疾病药物中的应用 | |
CN115364129B (zh) | 九节茶或其提取物、清热消炎宁制剂在制备抗冠状病毒药物中的应用及其制备方法 | |
CN113599376A (zh) | 鸢尾甲黄素a在制备防治支气管哮喘疾病药物中的应用 | |
WO2008095429A1 (fr) | Glycoprotéine destinée au traitement de maladies pulmonaires obstructives chroniques | |
CN103961654B (zh) | 一种白葡萄球菌片及其制备方法 | |
CN114948914B (zh) | 一种盐酸莫西沙星雾化吸入用溶液剂及其制备方法 | |
CN114129705B (zh) | 一种多肽在预防和治疗肺炎的药物中的应用 | |
CN108096242B (zh) | 一种治疗慢性阻塞性肺病的中药组合物 | |
CN111920785B (zh) | 异甘草酸或其盐的吸入制剂及其应用 | |
Zuo et al. | Effect of Maxingganshi decoction on the expression of STAT4 and STAT6 in lung tissues of rats with chronic obstructive pulmonary disease. | |
CN115137790A (zh) | 一种中药组合物在改善或治疗呼吸系统疾病中的用途 | |
CN115429845A (zh) | 一种川贝母总生物碱提取物在制备抗哮喘药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40030149 Country of ref document: HK |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200904 |